**Commentary**
Volume 10:03, 2024

Journal of Vasculitis

ISSN: 2471-9544 Open Access

# Comparative Analysis of Immunosuppressive Therapies for Takayasu Arteritis

**Jeffery Gabriela***

*Department of Infectious and Tropical Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA*

## Introduction

Takayasu arteritis is a granulomatous vasculitis of unknown etiology, predominantly affecting young women. The disease is characterized by inflammation of the aorta and its major branches, leading to stenosis, occlusion, and aneurysm formation. The clinical presentation of TA is variable, ranging from nonspecific systemic symptoms to severe vascular complications. Given the chronic and relapsing nature of TA, effective long-term management is crucial. Immunosuppressive therapies, including corticosteroids and various steroid-sparing agents, play a pivotal role in controlling disease activity and preventing irreversible vascular damage. This article reviews the current immunosuppressive treatment options for TA, comparing their efficacy and safety profiles.

## Description

A systematic literature review was conducted using databases such as PubMed, MEDLINE, and Cochrane Library. Studies included in the review were Randomized Controlled Trials (RCTs), cohort studies, and retrospective analyses evaluating the efficacy and safety of immunosuppressive therapies in TA. The primary outcomes assessed were disease remission rates, relapse rates, and adverse events associated with each therapy. Corticosteroids are the cornerstone of initial therapy for Takayasu Arteritis (TA), primarily due to their potent anti-inflammatory effects. These medications work by suppressing the immune response that drives the vascular inflammation characteristic of TA. Upon diagnosis, patients are typically started on high doses of corticosteroids, such as prednisone, to achieve rapid control of the inflammatory process. The usual starting dose ranges from 0.5 to 1 mg/kg per day, depending on the severity of the disease.

The goal of high-dose corticosteroid therapy is to induce remission, which is defined as the reduction or resolution of symptoms and the normalization of inflammatory markers such as Erythrocyte Sedimentation Rate (ESR) and C - reactive protein (CRP). Clinical studies have shown that corticosteroids can achieve remission in a significant proportion of patients with TA, often within weeks of initiation. However, the inflammatory nature of the disease frequently necessitates long-term treatment to maintain remission and prevent relapses. A major challenge in the management of TA with corticosteroids is the need to balance effective disease control with the potential for significant side effects. Prolonged use of high-dose corticosteroids is associated with a range of adverse effects, including osteoporosis, hyperglycemia, hypertension, weight gain, and increased susceptibility to infections. These side effects can significantly impact patients' quality of life and lead to additional health complications [1].

Methotrexate is commonly used as a corticosteroid-sparing agent in the treatment of Takayasu Arteritis (TA), valued for its efficacy in inducing and maintaining remission while reducing the need for long-term high-dose corticosteroids. Methotrexate is an antimetabolite and antifolate drug that exerts its immunosuppressive effects by inhibiting dihydrofolate reductase, an enzyme involved in DNA synthesis and cellular replication. This inhibition results in reduced proliferation of immune cells, which helps to control the inflammation associated with TA. In clinical practice, methotrexate is typically administered once weekly, either orally or by subcutaneous injection, with doses ranging from 15 to 25 mg per week. The drug's effectiveness in managing TA has been demonstrated in several studies and clinical trials, which have shown that methotrexate can significantly reduce disease activity and help maintain remission. Patients on methotrexate often experience a decrease in inflammatory markers such as Erythrocyte Sedimentation Rate (ESR) and C - reactive protein (CRP), alongside a reduction in clinical symptoms.

Methotrexate is generally well-tolerated, but it is not without its side effects. Common adverse effects include gastrointestinal disturbances (such as nausea, vomiting, and diarrhea), mucositis, and liver enzyme abnormalities. To mitigate these risks, patients are often prescribed folic acid supplements, which can help reduce the incidence of methotrexate-related side effects. Additionally, regular monitoring of liver function tests and complete blood counts is necessary to detect potential toxicity early and adjust the dosage accordingly [2,3].

Azathioprine is another important immunosuppressive agent used in the management of Takayasu Arteritis (TA), particularly as a corticosteroid-sparing medication. Azathioprine is a prodrug that is converted into its active form, 6-mercaptopurine, once inside the body. This active metabolite inhibits purine synthesis, which is crucial for the proliferation of lymphocytes and other rapidly dividing cells involved in the immune response. By interfering with DNA synthesis, azathioprine helps to suppress the overactive immune system that contributes to the inflammation seen in TA. In clinical practice, azathioprine is typically administered orally, with the dosage usually ranging from 1 to 2.5 mg/kg per day. The therapeutic effects of azathioprine in TA are gradual, often requiring several weeks to months to achieve optimal results. Azathioprine's role in the management of Takayasu arteritis is well-documented, and it is often used in combination with other immunosuppressive agents to achieve better disease control. Although it may not be effective for all patients, it remains a valuable option for many, particularly when corticosteroid-sparing is desired.

Mycophenolate Mofetil (MMF) is an immunosuppressive medication increasingly used in the management of Takayasu Arteritis (TA), particularly for patients who either cannot tolerate or do not respond adequately to other treatments. MMF is a prodrug that is converted into its active form, mycophenolic acid, which exerts its effects by inhibiting Inosine Monophosphate Dehydrogenase (IMPDH). This enzyme is crucial for the de novo pathway of purine synthesis, which is essential for the proliferation of lymphocytes and other immune cells. By blocking this pathway, MMF effectively reduces the activation and proliferation of these cells, thereby helping to control the inflammation associated with TA. The standard dosing regimen for MMF typically involves an initial dose of 1 to 2 grams per day, administered orally in divided doses. The therapeutic effects of MMF in TA

***Address for Correspondence:** Jeffery Gabriela, Department of Infectious and Tropical Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA, E-mail: Jefferygabriela32@gmail.com*



**Received:** 01 May, 2024, Manuscript No. jov-24-146014; **Editor Assigned:** 03 May, 2024, Pre QC No. P-146014; **Reviewed:** 15 May, 2024, QC No. Q-146014; **Revised:** 20 May, 2024, Manuscript No. R-146014; **Published:** 27 May, 2024, DOI: 10.37421/2471-9544.2024.10.242

often become apparent over several weeks, as it gradually reduces disease activity and stabilizes symptoms. Clinical studies and observational data suggest that MMF can be effective in inducing and maintaining remission in TA, with patients experiencing reductions in inflammatory markers such as Erythrocyte Sedimentation Rate (ESR) and C - reactive protein (CRP). This makes MMF a valuable option for managing TA, particularly in combination with or as an alternative to corticosteroids and other immunosuppressive agents.

Cyclophosphamide is reserved for severe or refractory cases of TA due to its potent immunosuppressive effects. It is effective in inducing remission but is associated with significant toxicity, including bone marrow suppression, hemorrhagic cystitis, and increased malignancy risk. Its use is generally limited to short-term induction therapy followed by maintenance with less toxic agents. Biologic agents, such as Tumor Necrosis Factor (TNF) inhibitors and Interleukin-6 (IL-6) receptor antagonists, are emerging options for refractory TA. Infliximab, a TNF inhibitor, has shown promise in inducing and maintaining remission in patients resistant to conventional therapies. Tocilizumab, an IL-6 receptor antagonist, has also demonstrated efficacy in reducing disease activity and vascular inflammation. However, the high cost and potential for serious infections limit their widespread use [4,5].

## Conclusion

Managing Takayasu arteritis requires a balance between controlling inflammation and minimizing treatment-related toxicity. Corticosteroids, while effective, necessitate the use of steroid-sparing agents like methotrexate, azathioprine, and MMF to reduce long-term side effects. Biologics represent a promising frontier for refractory cases but warrant further study. Future research should focus on optimizing treatment regimens and identifying biomarkers for personalized therapy in TA. The comparative analysis of immunosuppressive therapies for Takayasu arteritis highlights the importance of individualized treatment strategies. Corticosteroids remain the cornerstone of initial therapy, but their long-term use is limited by significant side effects. Methotrexate, azathioprine, and MMF are effective corticosteroid-sparing agents, with methotrexate often preferred due to its favorable efficacy and safety profile. Cyclophosphamide is reserved for severe cases, while biologics offer hope for refractory disease but require further investigation.

## Acknowledgement

None.

## Conflict of Interest

Authors declare no conflict of interest.

## References

1. Decker, Paul, Pierre Olivier, Jessie Risse and Stéphane Zuily, et al. "Tocilizumab and refractory Takayasu disease: four case reports and systematic review." *Autoimmun Rev* 17 (2018): 353-360.
2. Trimm, Emily and Kristy Red-Horse. "Vascular endothelial cell development and diversity." *Nat Rev Cardiol* 20 (2023): 197-210.
3. Legendre, Paul, Alexis Régent, Mathilde Thiebault and Luc Mouthon. "Anti-endothelial cell antibodies in vasculitis: A systematic review." *Autoimmun Rev* 16 (2017): 146-153.
4. Eichhorn, Jens, Dagmar Sima, Bernhard Thiele and Carsten Lindschau, et al. "Anti–endothelial cell antibodies in Takayasu arteritis." *Circulation* 94 (1996): 92396-2401.
5. Nityanand, S., K. Mishra, S. Shrivastava and G. Holm, et al. "Autoantibodies against cardiolipin and endothelial cells in Takayasu's arteritis: prevalence and isotype distribution." *J Rheumatol* 36 (1997): 923-924.

**How to cite this article:** Gabriela, Jeffery. "Comparative Analysis of Immunosuppressive Therapies for Takayasu Arteritis." *J Vasc* 10 (2024): 242.